Stephens lowered the firm’s price target on Option Care Health (OPCH) to $30 from $40 and keeps an Overweight rating on the shares. Adverse chronic infusion dynamics will weigh on top-line performance in 2026, the analyst tells investors in a post-Q1 note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPCH:
- Option Care Health price target lowered to $26 from $38 at Deutsche Bank
- Option Care Health: Execution Risks, CID Headwinds Prompt EBITDA Cut and Price Target Reduction to $23, Supporting Hold Rating
- Option Care Health Balances CID Hit With Stable Profits
- Option Care Health price target lowered to $32 from $38 at Citizens
- Option Care Health falls -29.7%